Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies.
about
Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensiCircumsporozoite protein as a potential target for antimalarialsMajor Histocompatibility Complex and Malaria: Focus on Plasmodium vivax InfectionVaccines for malaria: how close are we?Malaria modeling: In vitro stem cells vs in vivo modelsInsights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions.Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical MalariaEngineered resistance to Plasmodium falciparum development in transgenic Anopheles stephensi.Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum.Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.Fetuin-A, a hepatocyte-specific protein that binds Plasmodium berghei thrombospondin-related adhesive protein: a potential role in infectivity.Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes.In vivo testing of subunit vaccines against malaria sporozoites using a rodent system.Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccineEarly transcriptional responses of HepG2-A16 liver cells to infection by Plasmodium falciparum sporozoitesPre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections.Development of an in vitro assay and demonstration of Plasmodium berghei liver-stage inhibition by TRAP-specific CD8+ T cellsDevelopment of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopesRabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion.Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites.Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope.Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccineMalaria vaccine development.Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.Comparative biology of intracellular parasitism.Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimodDetection of human antibodies against Plasmodium falciparum sporozoites using synthetic peptides.Antibody-independent inhibition of Plasmodium falciparum in vitro cultures.Role of cysteines in Plasmodium falciparum circumsporozoite protein: interactions with heparin can rejuvenate inactive protein mutants.Protective value of elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium falciparum.Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunityInducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA.Estimating and testing haplotype-trait associations in non-diploid populations
P2860
Q24456431-DFE1D5D2-7C05-4D79-BDF7-B7DD9D669627Q26314437-B39DAFC2-CC8E-4547-A3D1-2ABF36CC7031Q26767472-AEF14426-F0EB-4E0B-B0F3-EA7F6A605E6DQ27024344-251DC484-3CC5-48AE-BA84-4392A28EC69EQ28071293-EAF382C7-745C-4B93-B9AA-675D58EE4813Q30380793-9B8D5696-7672-45B4-8DD6-73B21B03033EQ33318466-694F4DF4-5117-497F-AA37-1CABC2FCAE61Q33512110-82D8D32A-A792-49E7-A8F8-ECD441230163Q33646573-67E15963-2214-4C45-8B08-8E5865DCAAFBQ33886121-2FD73AC4-63A1-4949-AD90-0E705ECD2B09Q33960093-15A79339-5EE0-4E35-BA8B-78541C0A83DDQ34008562-1DC423A0-D38C-435E-BAFE-EAD9B5B6069BQ34034163-8ACEAFA8-9D0D-4190-82DC-EAC6E0EF9F3EQ34036184-B811ACCC-338C-4D4E-8268-B3034816FC22Q34055744-3CF537C0-E989-4AFC-A0FA-C15044B7B696Q34373653-63142D02-0B35-47A9-87EB-123A944AE9EFQ34546208-719E832D-D560-471E-A58C-EADB212DCD7DQ34546220-3D8F037E-5950-4EBF-AC10-52B76D8C93D1Q34889790-8963397E-8E29-46C5-92E0-A879E8D598C4Q35005868-288CED8D-6E0D-4CC2-88A1-761CE18B234DQ35128146-6F0AB60A-E8FB-4DA3-8A49-08CC7FBFFFCEQ35211719-73AE2BB0-5407-4F53-843B-918420053272Q35231780-C3917325-1899-4504-B882-BDCBD9D73A97Q35553683-91D82C52-4D01-4B88-BA65-FDE8DD46B072Q35590960-E0CDAA1D-B4EE-4B0D-A8DC-98C53D141D11Q35840477-5CDC96E0-3B05-41FC-80B9-2DC3C089A508Q36083687-A7CB6641-ED6B-4421-97BF-E93D53E7DEAFQ36353517-B0986CC2-9459-4244-ABFD-4A4D39BF00F7Q36641624-DA294FD8-62C9-4A94-8C9F-8FF899AF895AQ36773737-D9702987-A68D-4738-8846-9B39A5073037Q37023939-2A146A1F-F578-481C-995B-A7045645726EQ37061907-77AE102B-E2AE-4372-BC96-8B77695FCABCQ37075435-CEE9DD44-7F7D-45B0-885B-FE7214F61D39Q37134841-7395F385-21F6-4A74-9B56-0A818BEE22C7Q37184156-1E039401-A416-47CA-B64A-DB0BDCBD32CBQ37232082-C4923CB3-AD2E-477B-BD8C-EFCDB5D75FF6Q37241837-5F144B1A-065A-44DB-9CC8-C5280A4CBFD0Q37254129-D476EAF7-0F11-4BD1-87DB-258CE68D9DD1Q37264722-D1468724-BCF6-4295-A6F5-1A69BDDD3D67Q37445034-2F4F1219-2B5D-487F-98AA-E4BC9C78A797
P2860
Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies.
description
1984 nî lūn-bûn
@nan
1984 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@ast
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@en
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@nl
type
label
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@ast
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@en
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@nl
prefLabel
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@ast
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@en
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@nl
P2093
P921
P1476
Inhibition of entry of Plasmod ...... ssay of protective antibodies.
@en
P2093
Hollingdale MR
Schwartz AL
Tharavanij S
P304
P407
P577
1984-02-01T00:00:00Z